SEALSQ has led a €130 million Series A funding round for Quobly, a company developing silicon-based quantum processors, to accelerate industrial deployment of secure quantum computing systems. This investment, made via SEALSQ's Quantum Fund, strengthens their partnership to integrate post-quantum cryptography with quantum hardware, aiming to create sovereign, secure quantum platforms for critical sectors like defense and finance. SEALSQ CEO Carlos Moreira will join Quobly's board, underscoring the strategic importance of this collaboration in advancing quantum technology infrastructure in Europe. The move supports SEALSQ's broader Quantum Vertical Sovereign Stack strategy to build trusted quantum systems from hardware to software.
Johnson & Johnson's nipocalimab, a novel FcRn blocker, met its primary endpoint by significantly reducing disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE) at 24 weeks, with benefits sustained through 52 weeks in a...
Johnson & Johnson announced new Phase 2 data for nipocalimab, an immunoselective FcRn blocker, showing greater clinical response in Sjögren's disease patients with elevated autoantibodies and IgG levels. The drug reduced disease activity and symptoms...
Celestica has shifted from low-margin electronics assembly to a high-growth leader in connectivity and cloud solutions, benefiting from hyperscaler capital expenditures and AI infrastructure demand. The company's Q1 results showed 80% year-over-year ...
Willis Towers Watson's shares have fallen about 20% over the past year amid concerns about AI disrupting its business. However, its specialized insurance broking and consulting services are less vulnerable to AI than more commoditized segments, and A...
DBV Technologies has begun screening the first participant in its phase 2 THRIVE clinical trial to test the VIASKIN Peanut patch on infants aged 6 to 12 months with peanut allergies. The study aims to evaluate the patch's safety and effectiveness in ...
